Literature DB >> 15947889

Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation.

Hylton V Joffe1, Gail K Adler.   

Abstract

Aldosterone, the final product of the renin-angiotensin-aldosterone system, is classically viewed as a regulator of renal sodium and potassium handling, blood volume, and blood pressure. Recent studies suggest that aldosterone can cause microvascular damage, vascular inflammation, oxidative stress and endothelial dysfunction. In animal models, aldosterone-mediated vascular injury in the brain, heart, and kidneys leads to stroke, myocardial injury, and proteinuria. These effects may be modified by dietary salt intake; aldosterone-mediated vascular damage is increased in susceptible animals fed a high-salt diet compared to a low-salt diet despite lower plasma aldosterone levels on the high-salt diet. In humans, there is a growing literature supporting the adverse effects of aldosterone in heart failure, hypertension, left ventricular hypertrophy, and renal disease. Aldosterone receptor antagonists are beneficial even in patients on angiotensin converting enzyme inhibitors and attenuate aldosterone-mediated vascular injury by mechanisms that appear to be independent of changes in systolic blood pressure. This review focuses on the adverse effects of aldosterone on the vascular system and describes our current understanding of the underlying mechanisms for this injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947889     DOI: 10.1007/s10741-005-2346-0

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  38 in total

1.  50th anniversary of aldosterone.

Authors:  Jonathan S Williams; Gordon H Williams
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

2.  Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.

Authors:  N J Brown; K S Kim; Y Q Chen; L S Blevins; J H Nadeau; S G Meranze; D E Vaughan
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

3.  Albuminuria in untreated patients with primary aldosteronism or essential hypertension.

Authors:  J M Halimi; A Mimran
Journal:  J Hypertens       Date:  1995-12       Impact factor: 4.844

4.  Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading.

Authors:  Diego V Martinez; Ricardo Rocha; Mamiko Matsumura; Eveline Oestreicher; Margarita Ochoa-Maya; Weranuj Roubsanthisuk; Gordon H Williams; Gail K Adler
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

5.  Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Authors:  Ricardo Rocha; Amy E Rudolph; Gregory E Frierdich; Denise A Nachowiak; Beverly K Kekec; Eric A G Blomme; Ellen G McMahon; John A Delyani
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

6.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

Authors:  R Rocha; P N Chander; K Khanna; A Zuckerman; C T Stier
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

Review 7.  Endothelial function. From vascular biology to clinical applications.

Authors:  Dominik Behrendt; Peter Ganz
Journal:  Am J Cardiol       Date:  2002-11-21       Impact factor: 2.778

8.  Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma.

Authors:  G P Rossi; A Sacchetto; E Pavan; P Palatini; G R Graniero; C Canali; A C Pessina
Journal:  Circulation       Date:  1997-03-18       Impact factor: 29.690

9.  Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.

Authors:  D M Kerins; Q Hao; D E Vaughan
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole.

Authors:  Shuji Arima; Kentaro Kohagura; Hong-Lan Xu; Akira Sugawara; Akira Uruno; Fumitoshi Satoh; Kazuhisa Takeuchi; Sadayoshi Ito
Journal:  Hypertension       Date:  2003-12-22       Impact factor: 10.190

View more
  24 in total

1.  Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults.

Authors:  Jennifer N Cooper; Ping Tepper; Emma Barinas-Mitchell; Genevieve A Woodard; Kim Sutton-Tyrrell
Journal:  Clin Exp Hypertens       Date:  2011-10-18       Impact factor: 1.749

Review 2.  Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease.

Authors:  Laura D Kubzansky; Gail K Adler
Journal:  Neurosci Biobehav Rev       Date:  2009-07-22       Impact factor: 8.989

Review 3.  Systemic inflammation in heart failure--the whys and wherefores.

Authors:  Arne Yndestad; Jan Kristian Damås; Erik Oie; Thor Ueland; Lars Gullestad; Pål Aukrust
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.214

Review 4.  Mineralocorticoid receptors in vascular function and disease.

Authors:  Amy McCurley; Iris Z Jaffe
Journal:  Mol Cell Endocrinol       Date:  2011-06-24       Impact factor: 4.102

5.  Cooperative Role of Mineralocorticoid Receptor and Caveolin-1 in Regulating the Vascular Response to Low Nitric Oxide-High Angiotensin II-Induced Cardiovascular Injury.

Authors:  Luminita H Pojoga; Tham M Yao; Lauren A Opsasnick; Waleed T Siddiqui; Ossama M Reslan; Gail K Adler; Gordon H Williams; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2015-07-16       Impact factor: 4.030

6.  Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice.

Authors:  Luminita H Pojoga; Zuzana Adamová; Abhinav Kumar; Amanda K Stennett; Jose R Romero; Gail K Adler; Gordon H Williams; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-02       Impact factor: 4.733

7.  Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways.

Authors:  Alexander W Krug; Lena Allenhöfer; Robert Monticone; Gaia Spinetti; Michael Gekle; Mingyi Wang; Edward G Lakatta
Journal:  Hypertension       Date:  2010-04-26       Impact factor: 10.190

8.  Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha.

Authors:  C A Carvajal; A A Herrada; C R Castillo; F J Contreras; C B Stehr; L M Mosso; A M Kalergis; C E Fardella
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

9.  Estrogen reduces aldosterone, upregulates adrenal angiotensin II AT2 receptors and normalizes adrenomedullary Fra-2 in ovariectomized rats.

Authors:  Miroslava Macova; Ines Armando; Jin Zhou; Gustavo Baiardi; Dmitri Tyurmin; Ignacio M Larrayoz-Roldan; Juan M Saavedra
Journal:  Neuroendocrinology       Date:  2008-08-04       Impact factor: 4.914

10.  Morphological and molecular changes of the myocardium after left ventricular mechanical support.

Authors:  Hideo A Baba; Jeremias Wohlschlaeger
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.